Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
出版年份 2011 全文链接
标题
Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 54, Issue 4, Pages 568-574
出版商
Oxford University Press (OUP)
发表日期
2011-12-08
DOI
10.1093/cid/cir830
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection
- (2011) Ellie J. C. Goldstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
- (2011) Kathleen M. Mullane et al. CLINICAL INFECTIOUS DISEASES
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- (2011) F. Babakhani et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fidaxomicin (OPT-80) for the treatment ofClostridium difficileinfection
- (2010) Mark Miller EXPERT OPINION ON PHARMACOTHERAPY
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
- (2009) D.M. Citron et al. ANAEROBE
- Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
- (2008) J. R. O'Connor et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile
- (2008) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses
- (2008) Y. K. Shue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
- (2008) T. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- (2008) T. J. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis
- (2008) M. Kurabachew et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started